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Abstract     
The synthesis of novel 7-aryl-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-ones is described 
including a one-step Mannich-type reaction followed by intramolecular ring closure of ethyl 
3-methylpyridazine-4-carboxylate and aldimines, catalysed by the Lewis acid Cu(OTf)2 under 
microwave heating. This synthesis opens up possibilities to access this unexplored scaffold for 
medicinal chemistry.  
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Introduction    
 
In the search for new biologically active compounds and drugs, extensive research is based on 
the synthesis of natural-like or small molecules. In this regard, the theory of privileged scaffolds, 
structures which can interact with high affinity to a broad range of (unrelated) receptors, 
provides new insights and hope for the synthesis of new active compounds.1 They are typically 
rigid and polycyclic heteroatomic systems, able to orient numerous substituents in the three-
dimensional space surrounding these scaffolds.2 Because these privileged structures furnish 
activities towards different receptors, they are considered excellent lead compounds, especially 
when only little is known about the structure of the receptors. Because the amount of new drugs 
is declining, despite the large amount of sources and research that are invested in this research, 
new scaffolds need to be explored. Therefore, increasing the chemical diversity in the field of 
heterocyclic chemistry is of great interest for the pharmaceutical industry. 
General Papers  ARKIVOC 2014 (vi) 139-155 
 Page 140 ©ARKAT-USA, Inc. 
 In the course of our research towards innovative heterocyclic scaffolds, our interests and 
efforts were guided towards the synthesis of 7-aryl-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-
ones. Dihydroisoquinolinones and dihydronaphthyridinones (the benzo- and pyrido-analogues 
respectively) are widely reported and investigated. Dihydroisoquinolinones 1 for example can be 
used for the treatment of various disease conditions mediated by the regulation of 17α-
hydroxylase/C17,20-lyase,3 whereas dihydronaphthyridinones 2 interact as mGluR5 allosteric 
modulators.4 7,8-Dihydropyrido[4,3-c]pyridazin-5(6H)-ones 3 however, are only scarcely 
reported in scientific literature. The only references (which came up of a Scifinder search) 
disclose the scaffold with one or more extra aromatic rings annelated to the scaffold.5,6,7 The 
amide-reduced analogues 5,6,7,8-tetrahydropyrido[4,3-c]pyridazines are only reported in two 
references.8,9 The 7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-one scaffold as such is still unknown 
in the scientific literature, leaving an opportunity towards the synthesis of a new possible 
privileged scaffold. 
 
 
 
 The synthesis of this new scaffold extends our research towards innovative bio-active 
heterocyclic scaffolds, in which small and natural-like molecules were discovered as anti-cancer 
chalcone derivatives,10 insect-repellant/antifeedant methanoproline analogues,11,12 or epibatidine-
like nicotinic acetylcholine receptors inhibitors.13,14 Further, the synthesis of new previously 
unreported scaffolds, 4-(trifluoromethyl)-7,8-dihydroquinolin-5(6H)-ones and 
4-(trifluoromethyl)-5,7,8,9-tetrahydro-6H-pyrido[3,2-b]azepin-6-ones,15 and 5,8-disubstituted 
5,6,8,9-tetrahydro-4H,7H-2,5,6a,8,9a-pentaazaphenalene-1,3-diones were discovered,16 
broadening the chemical diversity of possible privileged scaffolds. 
 In this paper, the synthesis of 7-aryl-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-ones is 
reported, synthetized by a one-step Mannich-type reaction followed by ring closure of ethyl 
3-methylpyridazine-4-carboxylate and aldimines. The reactions were performed under Cu(OTf)2 
catalysis and microwave heating. 
 
 
Results and Discussion  
 
The synthesis started with the synthesis of ethyl 3-methylpyridazine-4-carboxylate 7 (Scheme 1). 
Two routes were explored, one starting from ethyl acetoacetate 4, the other starting from ethyl 
2-chloroacetoacetate 8. In a first entry, ethyl acetoacetate was mono-allylated with 1.2 
equivalents of allyl iodide and 1.1 equivalents of sodium hydride in dry THF for 1 hour 30 
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minutes at room temperature, leading to ethyl 2-allylacetoacetate 5 by column chromatography 
in 79% yield.17 Allylation with allyl bromide and sodium hydride or a palladium catalyzed Trost-
allylation with allyl bromide resulted in either diallylation or a mixture of mono- and diallylated 
product.  
 
Scheme 1. Synthesis of ethyl 3-methylpyridazine-4-carboxylate (7). 
 
 Having the alkene in hand, an ozonolysis was performed to obtain the free aldehyde ethyl 
2-acetyl-4-oxobutanoate 6. This was performed by bubbling ozone through a solution of ethyl 
2-allylacetoacetate 5 in dichloromethane and methanol (ratio 10:1) at -78°C for 30 minutes, to 
which a trace amount of Sudan III was added as an indicator. An equimolar amount of 
polymer-bound PPh3 was added for the reductive work-up of the intermediate ozonides and after 
1 hour of slow stirring at room temperature, the reaction mixture was filtered and evaporated.18 
Analysis of the reaction mixture by 1H-NMR demonstrated a 52% conversion of the alkene 
towards the aldehyde. Because no full conversion of 5 and no pure aldehyde 6 could be obtained, 
the crude mixture of 5 and 6 was used as such in the next step for the synthesis of ethyl 
3-methylpyridazine-4-carboxylate 7. 
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 The synthesis of ethyl 3-methylpyridazine-4-carboxylate 7 was performed by the reaction of 
crude 6 with hydrazine.18 A solution of the reaction mixture in ethanol was slowly treated with 
0.7 equivalents of hydrazine monohydrate at 0°C. The reaction mixture was allowed to warm to 
room temperature and was stirred for 2 hours 30 minutes. Thereafter, 1.5 equivalents of sodium 
nitrite, dissolved in water, and acetic acid were added and the mixture was again stirred for 1 
hour at room temperature. After column chromatography, the end product was obtained in 39% 
yield (two steps) as yellow-brownish crystals. Taken this low (overall) yield, the small scale and 
the troublesome synthesis of pyridazine 7 into account, this pathway was abandoned and a new 
pathway starting from ethyl 2-chloroacetoacetate was investigated.  
 The new synthesis pathway towards ethyl 3-methylpyridazine-4-carboxylate 7 started with 
the formation of ethyl 2-chloroacetoacetate N-methoxycarbonylhydrazone 10.19 Ethyl 
2-chloroacetoacetate 8 was dissolved in dry diethyl ether and 1 equivalent of methyl 
hydrazinocarboxylate 9 was added. After stirring for 24 hours at room temperature, the 
precipitate was filtered off and washed with petroleum ether, resulting in pure ethyl 
2-chloroacetoacetate N-methoxycarbonylhydrazone 10 as a white powder in 94% yield. 
 The hydrazone 10 was subsequently converted into 4-ethyl 1-methyl 6-ethoxy-3-methyl-5,6-
dihydropyridazine-1,4(4H)-dicarboxylate 12 via treatment with sodium bicarbonate and a 
subsequent inverse electron demand hetero Diels-Alder reaction.20  
 Hydrazone 10 was dissolved in a 2:1 diisopropyl ether:water mixture and 1.06 equivalents of 
sodium bicarbonate were added. The reaction mixture discoloured immediately and release of 
gas was noticed and the 1,2-diaza-1,3-diene 11 was formed. After 2 hours of stirring at room 
temperature, the aqueous phase was discarded and the red organic phase was dried over 
magnesium sulfate. Because the isomeric mixture of 11 (of which the E-isomer is the major 
component) polymerises at room temperature and has explosive properties upon heating, thereby 
prohibiting purification by distillation, 11 was used as an unpurified mixture of isomers in 
diisopropyl ether in the next step.21  
 For the inverse electron demand hetero Diels-Alder reaction, 2.3 equivalents of ethyl vinyl 
ether were added to the dried solution of 11 in diisopropyl ether. The mixture was brought to 
reflux temperature and heated overnight. The reaction mixture was evaporated, resulting in a 
yellow oil of 4-ethyl 1-methyl 6-ethoxy-3-methyl-5,6-dihydropyridazine-1,4(4H)-dicarboxylate 
12 in 91% yield over two steps. This Diels-Alder product 12 was obtained as a cis-trans mixture. 
Since 12 had to be converted to ethyl 3-methylpyridazine-4-carboxylate 7 in the next step, no 
purification nor separation of the isomers was necessary and 12 was used as such in the next 
step.  
 The last step in the synthesis of ethyl 3-methylpyridazine-4-carboxylate 7 is the oxidation of 
12 with bromine in acetic acid.20 The crude 12 was dissolved in acetic acid and 1.2 equivalents 
of bromine were slowly added. This resulted in the formation of a brown reaction mixture and 
the production of gas. After stirring for 24 hours at room temperature, diisopropyl ether was 
added, resulting in the formation of a precipitate which was filtered and washed with diisopropyl 
ether. Toluene was added and evaporated to remove residual acetic acid in an azeotropic 
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distillation.  The residue was dissolved in water and trace amounts of small impurities were 
filtered off. The filtrate was neutralized by sodium bicarbonate and sodium chloride was added. 
The mixture was extracted with diisopropyl ether and the organic phase was dried over 
magnesium sulfate and evaporated, resulting in red-brown crystals of 7. According to 1H-NMR 
and LC-MS analysis, these crystals consisted of 7 in very high purity. Recrystallization from 
diethyl ether did not improve the purity. After column chromatography and subsequent 
recrystallization from diethyl ether, colorless crystals of 7 were obtained in 72% yield, having 
the same 1H-NMR and LC-MS purity as the red-brown crystals.  
 The latter synthesis for ethyl 3-methylpyridazine-4-carboxylate was used starting from ethyl 
2-chloroacetoacetate 8 because the first synthesis route, starting from ethyl acetoacetate 3, did 
not offer satisfactory results. This second route not only comprised a more practical synthesis, it 
could also be executed on gram scale and in high (overall) yields. 
 For the synthesis of the pyrido[4,3-c]pyridazines, ethyl 3-methylpyridazine-4-carboxylate 7 
was reacted with aldimines. Different aldimines were synthetized via a straightforward procedure 
(Scheme 2).22 The appropriate aldehyde 13 was dissolved in dichloromethane and 1.05 
equivalents of the corresponding amine 14 was added. After stirring at reflux temperature for 3 
hours in the presence of 1.5 equivalents of magnesium sulfate, the precipitate was filtered and 
the aldimine 15 was obtained in almost always quantitative yield, without the need for 
purification. Also, the N-benzylidene-p-toluenesulfonamide 16 was synthetized by refluxing 1 
equivalent of p-toluenesulfonamide and 1 equivalent of benzaldehyde under Dean-Stark 
conditions, resulting in 87% of 16 after recrystallization from diethyl ether.23  
 
 
 
Scheme 2.  Synthesis of aldimines 15-16. 
 
 The synthetized ethyl 3-methylpyridazine-4-carboxylate 7 and N-benzylidene- 
p-toluenesulfonamide 16 were used in a Mannich-type reaction to furnish the addition product 18 
(Scheme 3, Table 1). Ethyl 3-methylpyridazine-4-carboxylate 7 and N-benzylidene- 
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p-toluenesulfonamide 16 were dissolved in dry THF in a pressure vial under an inert argon 
atmosphere and were heated at 120°C. Copper(II)triflate (9.4 mol%) was added, together with an 
equal amount of 1,10-phenanthroline as a ligand to solubilize the copper catalyst. This copper 
salt does not only activate imine 16 by acting as a Lewis acid, but also shifts the equilibrium 
between 7 and 7a towards the enamine by the formation of a metal enamide species 17.24 In a 
first entry, an excess of 7 was used and the reaction was stirred for 1 hour 40 minutes, resulting 
in a conversion of 9% of 7 to 18. When 5 mol% of catalyst was added and the reaction was 
performed for 24 hours, the conversion increased to 30% (entry 2). However, the isolated yield 
of 18 was very low, due to a very difficult purification by column chromatography. Increasing 
the equivalents of 16 did lead to an increase in yield after 20 hours (entry 3), while an extensive 
reaction time of 89 hours only offered a moderately improved yield (entry 4). Adding 1.5 
equivalents of DIPEA to trap the expelled proton (entry 5) did not improve the reaction outcome 
as well. 
 
 
Scheme 3. Synthesis of 18. 
 
Table 1. Conditions for the synthesis of 18 
Entry Eq 16 Eq Cu(OTf)2 
Eq 1,10-phenanthroline Time 
Conversion 
(%)a 
Yield 
(%) 
1 0.4 0.094 1h40 9 - 
2 0.4 0.05 24h 30 2 
3 0.95 0.05 20h - 33 
4 0.95 0.05 89h - 50 
5 0.95 0.05 ; 1.5 eq DIPEA 70h 21 - 
a Based on NMR. 
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 Nevertheless, having the Mannich-type addition product 18 in hand, the ring closure towards 
7-phenyl-6-tosyl-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-one 19 could be attempted (Scheme 
4). In a first attempt, 18 was dissolved in DMSO and this solution was added to a solution of 2.5 
equivalents of sodium hydride in DMSO and was stirred at 80°C, but no cyclized product could 
be recovered.25 When the solvent was changed to dioxane, no ring closure to 19 proceeded, but 
instead the saponification to 3-(2-(N-tosyl)-amino-2-phenylethyl)pyridazine-4-carboxylic acid 20 
occurred. The last attempt comprised stirring 18 in a 10:1 dichloromethane:glacial acetic acid 
mixture overnight at room temperature. Also under these acidic reaction conditions, 19 could not 
be obtained. 
 
 
 
Scheme 4.  Attempted synthesis of 19. 
 
 The desired ring closure most probably did not occur due to the (too) strong electron 
withdrawing potency of the N-tosyl group. Therefore, alternative aldimines were used in the 
pursuit of 7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-ones. 
 The copper(II) triflate-catalyzed Mannich-type reaction was repeated with N-benzylidene-
benzylamine 15b (Scheme 5, Table 2). Ethyl 3-methylpyridazine-4-carboxylate 7, 0.95 
equivalents of N-benzylidene-benzylamine 15b, 5 mol% copper(II)triflate and 
1,10-phenanthroline were dissolved in dry THF in a pressure vial under an inert nitrogen 
atmosphere. After 127 hours, the reaction mixture was filtered over a plug of silica involving 
washing with a large amount of ethyl acetate to remove the copper salts and the filtrate was 
evaporated. Purification by column chromatography yielded 6-benzyl-7-phenyl-7,8-
dihydropyrido[4,3-c]pyridazin-5(6H)-one 22b in 8% yield (entry 1). Interestingly, the Mannich-
type addition and the direct ring closure occurred simultaneously, without the isolation of the 
Mannich-type adduct 21b, which could not be observed in the reaction mixture.  
 An increase of the amounts of copper(II) triflate and 1,10-phenanthroline to 20 mol% and an 
increase in reaction temperature to 140°C resulted in a conversion of 44% (entry 2). The 
conversion could be enhanced by the use of 2 equivalents of 15b, resulting in a conversion of 
74% and a yield of 54% (entry 3). Because of the very slow reaction rate resulting in an 
extremely long reaction time, even at 120-140°C, the influence of microwave (MW) heating was 
evaluated in the next entries (entries 4-6). When microwave heating was applied at 165°C for 25 
minutes, no reaction product could be isolated (entry 4). These conditions were too harsh for the 
microwave vial septum, resulting in the loss of the reaction mixture. When a temperature of 
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135°C was maintained for 9 hours, a conversion of 85% and the corresponding yield of 55% was 
obtained (entry 5). The reaction time could be reduced to 3 hours when 3 equivalents of imine 
15b were added (entry 6). 
 
 
 
Scheme 5.  Synthesis of 22b. 
 
Table 2.  Conditions for the synthesis of 22b 
Entry Eq 15b Eq Cu(OTf)2 
Eq 1,10-phenanthroline 
Conditions Conversion 
(%)a 
Yield 
(%) 
1 0.95 0.05 120°C, 127h 
pressure vial 
- 8 
2 0.95 0.2 120°C, 72h, 
140°C, 144h 
pressure vial 
44 - 
3 2 0.2 120°C, 48h 
140°C, 144h 
pressure vial 
74 54 
4 2 0.2 165°C, 25min, 
MW 
- - 
5 2 0.2 135°C, 9h, MW 85 55 
6 3 0.2 135°C, 3h, MW 82 48 
a Based on NMR. 
 
 In an analogous reaction, N-benzylidene-(4-methoxybenzyl)amine 15a was used as the 
aldimine. After purification, not only the desired 6-(4-methoxybenzyl)-7-phenyl-7,8-
dihydropyrido[4,3-c]pyridazin-5(6H)-one 22aa was obtained, but also 6-benzyl-7-(4-
methoxyphenyl)-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-one 22ab as an inseparable mixture 
(3:2 22aa:22ab or vice versa) in 53% total yield.  
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Scheme 6.  Synthesis of 22a. 
 
 These two isomers 22aa/22ab were formed due to isomerization of 15a to N-(4-
methoxybenzylidene)-benzylamine via a [1,3]-proton shift under the prevailing reaction 
conditions. Therefore, only aldimines 15b-g in which both aromatic moieties are substituted with 
the same R-group could be used in further reactions. In these cases, isomerization of the aldimine 
does not lead to a mixture of 7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-one isomers. 
 To broaden the scope of the reaction towards the synthesis of 7-aryl-7,8-dihydropyrido[4,3-
c]pyridazin-5(6H)-ones 22b-g, different aldimines 15b-g have been used. The reaction was 
performed overnight (15 hours) in order to obtain the highest possible yields of 22b-g.  
 
 
Scheme 7.  Synthesis of 22b-g. 
 
 After filtration of the reaction mixture over silica, pure compounds were only obtained after 
several consecutive purifications via column chromatography, due to the very similar retention 
factors of 22b-g and the unreacted ethyl 3-methylpyridazine-4-carboxylate 7. An alternative 
work-up procedure comprised stirring of the filtrate residue in a 1:2 2M aq. NaOH:THF solution 
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for 45 minutes. In this way, the unreacted ethyl 3-methylpyridazine-4-carboxylate 7 was 
hydrolyzed into the corresponding 3-methylpyridazine-4-carboxylate. When the organic phase 
was evaporated, 22b-g could be extracted with dichloromethane, together with the excess of 
aldimine 15b-g. The pure compounds 22b-g were now easily obtained via column 
chromatography in moderate to good yields as yellow viscous oils. The chloro derivatives 
resulted in somewhat lower yields, probably due to the interaction of the chlorine atoms with the 
copper catalyst.  
 Attempts to further improve the yields were performed by a) the portion wise addition of the 
catalysts and aldimines, b) prolonging the reaction time up to 35 hours or c) using a dilute 
reaction mixture to increase the solubility of the starting ethyl 3-methylpyridazine-4-carboxylate 
7. Unfortunately, these attempts were not successful.  
 The conformational structure and spectroscopic data of the compounds 22b-g did offer some 
intriguing results. Due to the steric interaction of the aryl groups positioned on the N6 and 
C7-position, the C7-aryl group is forced into the pseudo-axial position (Figure 1).26 Also, the 
geometrical conformation led to a difference in 1H-NMR shift of around 2 ppm for the two 
diastereotopic geminal protons Ha and Hb in an AB-system from the amide-methylene group, due 
to the neighbouring amide carbonyl anisotropy.27 By the use of a NOESY-1H-NMR-experiment, 
proton Ha was assigned as the proton which is most closely positioned at Heq,c (δ ≈ 3.60 ppm). 
Because of the anisotropy of the carbonyl group, proton Hb has a much higher chemical shift (δ ≈ 
5.60 ppm). 
 
 
Figure 1.  Conformational structure of 22b-g. 
 
 This conformational structure was confirmed by the X-ray diffraction analysis of 6-(4-
fluorobenzyl)-7-(4-fluorophenyl)-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-one 22e of which the 
asymmetric unit and crystal unit cell are depicted in Figure 2 and Figure 3.  
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Figure 2. Asymmetric unit of the 
crystal structure of 22e, showing 
thermal displacement ellipsoids at the 
50% probability level and atom 
labeling scheme of the non-hydrogen 
atoms. 
 
Figure 3. Crystal unit cell 
of 22e, showing the not-
centrosymmetrical 
spacegroup P212121 
 
 Despite the difficult synthesis of the 7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-ones 22, 
requiring rather harsh conditions by microwave heating, we did succeed in the synthesis of this 
new scaffold.  
 
 
Conclusions 
 
In conclusion, a novel approach towards 7-aryl-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-ones 
22b-g is presented. The key step is a one-step Mannich-type reaction of ethyl 
3-methylpyridazine-4-carboxylate 7 and aldimines 15b-g followed by an intramolecular ring 
closure, catalysed by the Lewis acid Cu(OTf)2 under microwave heating. This ring closure 
occurred concomitantly with the Mannich-type reaction and the intermediate addition product 
could not be isolated nor observed. This new scaffold opens up new opportunities in the 
chemical space and in the field of heterocyclic chemistry for the pharmaceutical industry.  
 
 
Experimental Section  
 
General. High resolution NMR spectra were run on a Bruker Avance III Nanobay 400 MHz 
spectrometer 1H-NMR (400 MHz), 13C-NMR (100 MHz) and 19F-NMR (376.5 MHz). Peak 
assignments were obtained with the aid of DEPT, 2D-HSQC, 2D-COSY spectra. The 
compounds were dissolved in deuterated solvents and the used solvent is indicated for each 
compound. Low resolution mass spectra were recorded on an Agilent 1100 Series VS (ES, 
4000V) mass spectrometer. HRMS analysis was performed using an Agilent 1100 series HPLC 
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coupled to an Agilent 6210 TOF-Mass Spectrometer, equipped with ESI/APCI-multimode 
source. IR-spectra were obtained from a Perkin Elmer Spectrum One infrared spectrometer. The 
purification of reaction mixtures was performed by flash chromatography using a glass column 
with silica gel (Acros, particle size 0.035-0.070 mm, Pore diameter ca. 6 nm). All microwave 
reactions were performed in a CEM Discover Benchmate with a continuous power output from 0 
to 300 watt and a self-adjusting, single mode MW cavity. The reactions were performed in 10 
mL thick-walled Pyrex reaction vessels, closed with a ‘snap-on’ septa cap and equipped with a 
small stirring bar. A ramp time of maximum five minutes was used whereby the temperature was 
increased from room temperature to the desired one. This temperature was maintained during the 
course of the reaction for the indicated time. The temperature control system used a non-contact 
infrared sensor to measure the temperature on the bottom of the vessel and was used in a 
feedback loop with the on-board computer to regulate the temperature from 25 to 250 °C by 
adjusting the power output (1 Watt increments). Cu(OTf)2 and 1,10-phenanthroline were dried at 
60-80°C at 2-3 mbar for at least one hour before every use in the reactions. X-ray intensity data 
were collected on a Agilent Supernova Dual Source (Cu at zero) diffractometer equipped with an 
Atlas CCD detector using CuKα radiation (λ = 1.54178 Å) and ω scans. The images were 
interpreted and integrated with the program CrysAlisPro (Agilent Technologies). Using Olex2, 
the structure was solved by direct methods using the ShelXS structure solution program and 
refined by full-matrix least-squares on F2 using the ShelXL program package. Non-hydrogen 
atoms were anisotropically refined and the hydrogen atoms in the riding mode and isotropic 
temperature factors fixed at 1.2 times U(eq) of the parent atoms. The amide and amine hydrogen 
atoms were located from a difference electron density map and were unrestrained refined. 
CCDC-1020668 contains the supplementary crystallographic data for this paper and can be 
obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge 
Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44-1223-
336033; or deposit@ccdc.cam.ac.uk). 
 
Synthesis of ethyl 3-methylpyridazine-4-carboxylate (7) starting from ethyl 2-
chloroacetoacetate (8) 
Synthesis of ethyl 2-chloroacetoacetate N-methoxycarbonylhydrazone (10).19 Ethyl 
2-chloroacetoacetate (8) (16.21 g, 1eq) and hydrazinocarboxylate(9) (8.90 g, 1eq) was dissolved 
in 100 ml of dry ethyl ether in a 250 ml round-bottomed flask. After stirring for 24 hours at room 
temperature, the precipitate was filtered off and washed with 2 times 50 ml petroleum ether, 
resulting in pure ethyl 2-chloroacetoacetate N-methoxycarbonylhydrazone 10 as a white powder 
in 94% yield (22.24 g).                                
Synthesis of 4-ethyl 1-methyl 6-ethoxy-3-methyl-5,6-dihydropyridazine-1,4(4H)- 
dicarboxylate 12.20 Ethyl 2-chloroacetoacetate-N-methoxycarbonylhydrazone (10) (5 g, 1 eq) 
was dissolved in a 2:1 diisopropyl ether:water mixture  (35 ml:15 ml) and 1.06 equivalents (1.88 
g) of sodium bicarbonate were added. The reaction mixture discoloured immediately and release 
of gas was noticed and methyl 2-(-4-ethoxy-4-oxobut-2-en-2-yl)diazene-1-carboxylate 11 was 
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formed. After 2 hours of stirring at room temperature, the aqueous phase was discarded and the 
red organic phase was dried over magnesium sulfate.  
For the inverse electron demand hetero Diels-Alder reaction, 2.3 equivalents (4.69 ml) of ethyl 
vinyl ether were added to the dried solution of 11 in diisopropyl ether. The mixture was brought 
to reflux temperature and heated overnight. The reaction mixture was evaporated, resulting in 
5.23 g of a yellow oil of 4-ethyl 1-methyl 6-ethoxy-3-methyl-5,6-dihydropyridazine-1,4(4H)-
dicarboxylate 12 in 91% yield over two steps, without purification.  
Synthesis of ethyl 3-methylpyridazine-4-carboxylate (7).20  4-Ethyl 1-methyl 6-ethoxy-3-
methyl-5,6-dihydropyridazine-1,4(4H)-dicarboxylate (12) (18.48 g, 1eq) was dissolved in 250 ml 
of acetic acid in a 500 ml round-bottomed flask and 1.2 equivalents (4.05 ml) of bromine were 
slowly added. This resulted in the formation of a brown reaction mixture and the production of 
gas. After stirring for 24 hours at room temperature, 250 ml of diisopropyl ether was added, 
resulting in the formation of a precipitate which was filtered and washed with 2 times 50 ml of 
diisopropyl ether. 100 ml of toluene was added and evaporated to remove residual acetic acid in 
an azeotropic distillation. The residue was dissolved in 75 ml of water and trace amounts of 
small impurities were filtered off. The filtrate was neutralized by 7.3 g of sodium bicarbonate 
and 12 g of sodium chloride was added. The mixture was extracted with 3 times 75 ml 
diisopropyl ether and the organic phase was dried over magnesium sulfate and evaporated. After 
column chromatography  with ethyl acetate (Rf=0.38) and subsequent recrystallization from 
diethyl ether, 8.03 g of colorless crystals of 7 were obtained in 72% yield.  
 
General procedure for the synthesis of 7-aryl-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-
ones (22b-g). The synthesis of 6-benzyl-7-phenyl-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-one 
22b is representative. 1 Equivalent (0.2 g) of ethyl 3-methylpyridazine-4-carboxylate 7, 0.2 
equivalent (0.043 g) of 1,10-phenanthroline and 0.2 equivalent (0.087 g) of Cu(OTf)2 are added 
to a flame-dried microwave vial with stirring bar. To this mixture, 3 ml of dry THF were added. 
3 equivalents (0.705 g) of N-benzylidene-benzylamine 15b is dissolved in 2 ml of dry THF and 
added to the mixture. The aldimine vial is rinsed with 1 ml of dry THF. The microwave vial is 
stirred at room temperature for 1 minute while flushing the headspace with a nitrogen flow, 
before closing the microwave vial with a septum. The mixture is heated during 15 hours at 
135°C by the use of microwave irradiation. 
After reaction, the mixture was filtered over a small plug of silica with the use of 50 ml of ethyl 
acetate and the filtrate was evaporated. The residue was dissolved in 20 ml: 40 ml 2M 
NaOH:THF solution and stirred for 45 minutes at room temperature. The organic phase was 
evaporated and the water phase extracted with 3 times 30 ml dichloromethane. The combined 
organic phases were dried over magnesium sulphate, filtrated and evaporated. The residue was 
coated on silica and purified by silica gel column chromatography using a solvent gradient from 
1:1 Hexane:EtOAc to EtOAc. 
6-Benzyl-7-phenyl-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-one (22b). 1H-NMR (400MHz, 
CDCl3): δ 3.61 (1H, dd, J 16.6, 2.3Hz, CHCHaHb), 3.73 (1H, d, J 16.6Hz, CHCHaHb); 3.74 (1H, 
General Papers  ARKIVOC 2014 (vi) 139-155 
 Page 152 ©ARKAT-USA, Inc. 
d, JAB 14.8Hz, NCHaHb); 4.96 (1H, dd, J 6.8, 2.3Hz, NCHCH2), 5.77 (1H, d, JAB 4.8Hz, 
NCHaHb), 7.00-7.05 (2H, m, 2 × CHarom), 7.25-7.39 (8H, m, 8 × CHarom), 8.11 (1H, d, J 5.1Hz, 
NCHCH), 9.33 (1H, dd, J 5.1, 0.6Hz, NCHCH); 13C-NMR (100MHz, CDCl3): δ 36.4 (CHCH2), 
49.0 (NCH2), 57.5 (NCHCH2), 123.5 (NCHCH), 126.0 (2 × CHarom), 126.7 (COCq), 128.1 
(CHarom), 128.2 (2 × CHarom), 128.3 (CHarom), 129.0 (2 × CHarom), 129.2 (2 × CHarom), 136.4 
(NCH2Cq), 138.2 (NCHCq), 152.0 (NCHCH), 155.8 (CO), 162.2 (NCqCH2). IR (ATR, cm-1): 
νmax 3030, 1654. HRMS (ES, pos. mode): m/z (%) calc: 316.1444, exp: 316.1459 (100) [M+H+]. 
Chromatography: Hex/EtOAc 1/1 - EtOAc Rf 0.50 (EtOAc). Yield: 55%. 
6-(4-Methoxybenzyl)-7-(4-methoxyphenyl)-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-one 
(22c). 1H-NMR (400MHz, CDCl3): δ 3.56 (1H, dd, J 16.5, 2.4Hz, CHCHaHb), 3.66 (1H, dd, J 
16.5, 6.7Hz, CHCHaHb); 3.80 (1H, d, JAB 14.6Hz, NCHaHb); 3.75 (3H, s, OMe), 3.82 (3H, s, 
OMe), 4.90 (1H, dd, J 6.7, 2.4Hz, NCHCH2), 5.68 (1H, d, JAB 14.6Hz, NCHaHb), 6.78 (2H, d, J 
8.7Hz, 2 × CHCqO), 6.88 (2H, d, J 8.7Hz, 2 × CHCqO), 6.93 (2H, d, J 8.7Hz, 2 × CHCqCH), 
7.21 (2H, d, J 8.7Hz, 2 × CH2CqCH), 8.10 (1H, d, J 5.0Hz, NCHCH), 9.32 (1H, d, J 5.0Hz, 
NCHCH). 13C-NMR (100MHz, CDCl3): δ 36.6 (CHCH2), 48.2 (NCH2), 55.31 (OCH3), 55.33 
(OCH3), 56.7 (NCHCH2), 114.3 (2 × CHCqO), 114.5 (2 × CHCqO), 123.5 (NCHCH), 126.8 
(COCq), 127.2 (2 × CHCqCH), 128.4 (NCH2Cq), 129.7 (2 × CH2CqCH), 130.1 (NCHCq), 151.9 
(NCHCH), 155.9 (CO), 159.4 (CqOCH3), 159.5 (CqOCH3), 162.0 (NCqCH2). IR (ATR, cm-1): 
νmax 2930, 1654, 1510, 1244. HRMS (ES, pos. mode): m/z (%) calc: 376.1656, exp: 376.1653 
(100) [M+H+]. Chromatography: Hex/EtOAc 1/1 - EtOAc Rf 0.43 (EtOAc). Yield: 61%. 
6-(4-Methylbenzyl)-7-(4-methylphenyl)-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-one (22d). 
1H-NMR (400MHz, CDCl3): δ 2.28 (3H, s, CH3), 2.36 (3H, s, CH3), 3.57 (1H, dd, J 16.6, 2.2Hz, 
CHCHaHb), 3.66 (1H, d, JAB 14.7Hz, NCHaHb), 3.68 (1H, dd, J 16.6, 6.8Hz, CHCHaHb), 4.91 
(1H, dd, J 6.8, 2.2Hz, NCHCH2), 5.74 (1H, d, JAB=14.7Hz, NCHaHb), 6.90 (2H, d, J 8.1Hz, 2 × 
CHCqCH), 7.06 (2H, d, J 7.9Hz, 2 × CHCqCHCH), 7.17 (4H, br. s, 2 × CH2CqCHCH), 8.10 (1H, 
d, J 5.0Hz, NCHCH), 9.31 (1H, dd, J 5.0, 0.6Hz, NCHCH). 13C-NMR (100MHz, CDCl3): δ 21.1 
(CH3), 21.2 (CH3), 36.5 (CHCH2), 48.6 (NCH2), 57.0 (NCHCH2), 123.5 (NCHCH), 125.9 (2 × 
CHCqCH), 126.8 (COCq), 128.2 (2 × CH2CqCH), 129.6 (2 × CHCqCHCH), 129.8 (2 × 
CH2CqCHCH), 133.4 (CH2CqCH), 135.1 (CHCqCH), 137.8 (CH3Cq), 138.1 (CH3Cq), 151.9 
(NCHCH), 155.9 (CO), 162.0 (NCqCH2). IR (ATR, cm-1): νmax 2921, 1655. HRMS (ES, pos. 
mode): m/z (%) calc: 344.1757, exp: 344.1764 (100) [M+H+]. Chromatography: Hex/EtOAc 1/1 
- EtOAc Rf 0.47 (EtOAc). Yield: 63%. 
6-(4-Fluorobenzyl)-7-(4-fluorophenyl)-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-one (22e). 
1H-NMR (400MHz, CDCl3): δ 3.58 (1H, dd, J 16.5, 2.4Hz, CHCHaHb), 3.72 (1H, dd, J 16.5, 
6.7Hz, CHCHaHb), 3.70 (1H, d, JAB 14.7Hz, NCHaHb), 4.93 (1H, dd, J 6.7, 2.4Hz, NCHCH2), 
5.55 (1H, d, JAB 14.7Hz, NCHaHb), 6.92-7.07 (6H, m, 4 × FCqCH, 2 × FCqCHCH), 7.23-7.29 
(2H, m, 2 × FCqCHCH), 8.10 (1H, d, J 5.1Hz, NCHCH), 9.34 (1H, dd, J 5.1, 0.6Hz, NCHCH). 
13C-NMR (100MHz, CDCl3): δ 36.5 (CHCH2), 48.4 (NCH2), 57.1 (NCHCH2), 115.9 (d, J 
21.7Hz, 2 × FCqCH), 116.2 (d, J 21.9Hz, 2 × FCqCH), 123.5 (NCHCH), 126.5 (COCq), 127.7 (d, 
J 8.3Hz, 2 × FCqCHCH), 130.0 (d, J 8.1Hz, 2 × FCqCHCH), 132.0 (d, J 3.4Hz, FCqCHCHCq), 
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133.8 (d, J 3.1Hz, FCqCHCHCq), 152.1 (NCHCH), 155.5 (CO), 162.0 (NCqCH2), 162.50 (d, J 
248.5Hz, FCq), 162.53 (d, J 247.0Hz, FCq). 19F-NMR (376.5MHz, CDCl3): δ -113.8 to -113.7 (F, 
m), -113.3 to -113.2 (F, m). IR (ATR, cm-1): νmax 2924, 1662, 1507, 1221, 1158. HRMS (ES, 
pos. mode): m/z (%) calc: 352.1256, exp: 352.1253 (100) [M+H+]. Chromatography: Hex/EtOAc 
1/1 - EtOAc Rf 0.50 (EtOAc). CDCC: 1020668.Yield: 59%. 
6-(4-Chlorobenzyl)-7-(4-chlorophenyl)-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-one (22f). 
1H-NMR (400MHz, CDCl3): δ 3.59 (1H, dd, J 16.6, 2.3Hz, CHCHaHb), 3.72 (1H, d, J 16.6Hz, 
CHCHaHb), 3.75 (1H, d, JAB 15.0Hz, NCHaHb), 4.91 (1H, dd, J 6.7, 2.3Hz, NCHCH2), 5.65 (1H, 
d, JAB 15.0Hz, NCHaHb), 6.96 (2H, d, J 8.4Hz, 2 × CHarom), 7.22 (2H, d, J 9.0Hz, 2 × CHarom), 
7.24 (2H, d, J 9.0Hz, 2 × CHarom), 7.33 (2H, d, J 8.4Hz, 2xCHarom), 8.10 (1H, d, J 5.0Hz, 
NCHCH), 9.34 (1H, d, J 5.0, NCHCH). 13C-NMR (100MHz, CDCl3): δ 36.3 (CHCH2), 48.5 
(NCH2), 57.2 (NCHCH2), 123.6 (NCHCH), 126.4 (COCq), 127.3 (2 × CHarom), 129.2 (2 × 
CHarom), 129.4 (2 × CHarom), 129.6 (2 × CHarom), 134.1 (ClCq), 134.4 (ClCq), 134.7 (NCH2Cq), 
136.5 (NCHCq) 152.1 (NCHCH), 155.3 (CO), 162.1 (NCqCH2). IR (ATR, cm-1): νmax 2922, 
2853, 1659, 1091. HRMS (ES, pos. mode): m/z (%) calc: 384.0665, exp: 384.0672 (100) 
[M+H+]. Chromatography: Hex/EtOAc 1/1 - EtOAc Rf 0.42 (EtOAc). Yield: 30%. 
6-(2-Chlorobenzyl)-7-(2-chlorophenyl)-7,8-dihydropyrido[4,3-c]pyridazin-5(6H)-one (22g). 
1H-NMR (400MHz, CDCl3): δ 3.78 (2H, m, CHCH2), 4.12 (1H, d, JAB 15.0Hz, NCHaHb), 5.40-
5.43 (1H, m, NCHCH2), 5.53 (1H, d, JAB 15.0Hz, NCHaHb), 6.75-6.78 (1H, m, CHarom), 7.03-
7.08 (1H, m, CHarom), 7.17-7.22 (1H, m, CHarom), 7.24-7.32 (2H, m, CHarom), 7.36-7.42 (3H, m, 
CHarom), 8.13 (1H, d, J 5.0Hz, NCHCH), 9.34 (1H, d, J 5.1, NCHCH). 13C-NMR (100MHz, 
CDCl3): δ 33.8 (CHCH2), 47.3 (NCH2), 55.6 (NCHCH2), 123.5 (NCHCH), 126.2 (CHarom), 126.4 
(COCq), 127.2 (CHarom), 127.3 (CHarom), 129.55 (CHarom), 129.63 (CHarom), 129.9 (CHarom), 130.6 
(CHarom), 130.8 (CHarom), 132.8 (Cq,arom), 133.4 (Cq,arom), 134.1 (Cq,arom), 135.1 (Cq,arom), 152.0 
(NCHCH), 162.6 (CO), 162.6 (NCqCH2). IR (ATR, cm-1): νmax 2924, 1663, 1038. HRMS (ES, 
pos. mode): m/z (%) calc: 384.0665, exp: 384.0672 (100) [M+H+]. Chromatography: Hex/EtOAc 
1/1 - EtOAc Rf 0.49 (EtOAc). Yield: 36%. 
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